三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
现有CD3/DLL3双抗临床数据对比分析
现有CD3/DLL3双抗临床数据对比分析
其它
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:177KB
图片尺寸:2303*1250
同报告图片
/
4
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
所属报告:
医疗保健行业CD3双抗~实体瘤篇:挑战与机遇并存创新设计或带来突破-240703(28页).pdf
打包全文图表
相关数据
CD3/DLL3主要相关药物临床进展(截至2025H1)
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
收藏
行业数据
2025-07-15
原图定位
查看详情
安进的CD3/DLL3双抗Tarlatamab于2024年5月获FDA加速批准上市
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
收藏
行业数据
2025-05-13
原图定位
查看详情
安进的CD3/DLL3双抗Tarlatamab于2024年5月获FDA加速批准上市
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
收藏
行业数据
2024-12-31
原图定位
查看详情
全球CD3/DLL3双抗或多抗药物研发格局
fCDoja/lk4HlkI3np7AgICAgICAgICAgICAgICB8IOS9nOeUqOacuuWItiAgICAgICAgICAgICB8IOeglOWPkeacuuaehCAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg5Zyo56CU6YCC5bqU55eHICAgICAgICAgICAgICAgfCDlhajnkIPpmLbmrrUgfCDkuK3lm73pmLbmrrUgfCDnvo7lm73pmLbmrrUgfAp8LS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLXwtLS0tLS0tLXwtLS0tLS0tLXwKfCBmYXJsYXRhbWFiOyBBTUcgNzU3ICB8IENEMy9ETEwzIOWPjOaKlyAgICB8IEFtZ2VuOyDnmb7mtY7npZ7lt54gICAgICAgICAgICAgICAgIHwg5bCP57uG6IOe6IK655mMOyDnpZ7nu4/lhoXliIbms4zliY3liJfohbrnmYwgfCDmibnlh4bkuIrluIIgfCBJSUnmnJ/kuLTluoogfCDmibnlh4bkuIrluIIgfAp8IEJJIDc2NDUzMiAgICAgICAgICAgfCBDRDMvRExMMyDlj4zmipcgICAgfCBCSTsgT3hmb3JkIEJpb1RoZXJhcGV1dGljczsg5Lit5Zu955Sf54mp5Yi26I2vIHwg56We57uP5YaF5YiG5rOM6IK/55ikOyDlsI/nu4bog57ogrrnmYwgfCBJSeacn+S4tOW6iiB8IElJ5pyf5Li05bqKIHwgSUnmnJ/kuLTluoogfAp8IEhQTjMyMzsgSFBOMzI4ICAgICAgfCBETEwzL0NEMy9hbGJ1bWluIOS4ieaKlyB8IEhhcnBvb24gVGhlcmFwZXV0aWNzKE1lcmNrKSB8IOWwj+e7huiDnuiCuueZjDsg56We57uP5YaF5YiG5rOM5YmN5YiX6IW655mMIHwgSS9JSeacn+S4tOW6iiB8IOS4tOW6iuWJjSB8IEkvSUnmnJ/kuLTluoogfAp8IFpHMDA2ICAgICAgICAgICAgICAgfCBDRDMvRExMMyDkuInmipcgICAgfCBHZW5zdW4gQmlvcGhhcm1hICAgICAgICAgICAgICAgfCDlsI/nu4bog57ogrrnmYw7IOelnue7j+WGheWIhuazjOiCv+eYpCB8IEkvSUnmnJ/kuLTluoogfCBJL0lJ5pyf5Li05bqKIHwg5Li05bqK5YmNIHwKfCBRTFMzMTkwNCAgICAgICAgICAgIHwgQ0QzL0RMTDMg5Y+M5oqXICAgIHwg6b2Q6bKB5Yi26I2vICAgICAgICAgICAgICAgICAgICAgICAgfCDlrp7kvZPnmKQgICAgICAgICAgICAgICAgIHwgSeacn+S4tOW6iiB8IEnmnJ/kuLTluoogfCDkuLTluorliY0gfAp8IFJPNzYxNjc4OSAgICAgICAgICAgfCBETEwzLzQtMUJCL0NEMyDkuInmipcgfCBSb2NoZSAgICAgICAgICAgICAgICAgICAgICAgICAgfCDnpZ7nu4/lhoXliIbms4zogr/nmKQ7IOWwj+e7huiDnuiCuueZjCB8IEnmnJ/kuLTluoogfCDkuLTluorliY0gfCBJ5pyf5Li05bqKIHwKCui1hOaWmeadpea6kO+8muWMu+iNr+mtlOaWue+8jOmVv+axn+ivgeWIuOeglOeptuaJgA==
收藏
其它
2024-07-12
原图定位
查看详情
全球DLL3/CD3抗体进度(部分产品梳理)
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
收藏
其它
2024-07-10
原图定位
查看详情
全球CD3/DLL3双抗或多抗物发格局
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
收藏
其它
2024-07-04
原图定位
查看详情
不同CD3/DLL3双抗产品设计对比
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
收藏
其它
2024-07-04
原图定位
查看详情
Tarlatama具有全球首创的CD3/DLL3抗肿瘤作用机制
fCDnu4bog57nsbvlnosgICB8IOeJueW+gSAgICAgICAgICAgICAgICAgICAgICAgfAp8LS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgVGFybGF0YW1hYiB8IENEM+e7k+WQiOWfn+OAgURMTDPnu5PlkIjln5/jgIHml6DmlYjlupRGY+WfnyB8CnwgVOe7huiDniAgICAgIHwgQ0Qz44CBVOe7huiDnuaJqeWiniAgICAgICAgICAgICB8CnwgU0NMQ+e7huiDniAgIHwgRExMM+OAgeiCv+eYpOe7huiDnuWHi+S6oSAgICAgICAgIHwKCgrotYTmlpnmnaXmupDvvJrlronov5vlhazlj7hFU01P5bm05Lya5ryU56S65p2Q5paZ
收藏
其它
2024-02-27
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
安进的 Tarlatamab疗 上确实取得了突破,为临床治疗极为棘手的 SCLC带来 的治疗方案。但是 CRS 和神经系统毒 事件的安全 风险似乎未能避免, 此 FDA 对Tarlatamab附加了黑框警告。
其它
原图定位
当前图表所属:
医疗保健行业CD3双抗~实体瘤篇:挑战与机遇并存创新设计或带来突破-240703(28页).pdf
不同式的前列腺癌靶创物疗与安全对比
PSMA/CD3双抗在产品格局与进展
全球CD3/EGFR双抗格局对比
全球CD3/CLDN18.2双抗开发格局
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》